Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Valerio Therapeutics Société anonyme

WhiteLab Genomics develops software solutions leveraging machine learning and graph knowledge technology to assist in the discovery and design of genomic therapies.

WhiteLab Genomics

Valerio Therapeutics is a clinical-stage biotechnology company that develops innovative DNA decoy therapeutics for oncology and inflammatory diseases. Self-described as leading in the development of first-in-class treatments.

Metric
Company Name	Valerio Therapeutics Société anonyme	WhiteLab Genomics
Symbol	ALVIO
MSH ID	COM:VALERIOTX	COM:WHITELABGX
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	FR	FR
Stage		Seed
Employee Count	19
Website	valeriotx.com	whitelabgx.com
LinkedIn
Founders

Metric
Market Cap	16.36M
Enterprise Value
Monthly Web Traffic		2.03K
Web Traffic Growth		0.35
Valuation
Raised Capital		10M

Metric
Revenue	1.90M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.34M
EBITDA	-19.62M
Operating Income	-20.12M
Net Income	-21.49M
EPS	-0.16
Diluted EPS	-0.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.80
Operating Profit Margin	-9.31
EBITDA Margin	-10.32
Net Profit Margin	-9.15
Return on Equity	-0.87
Return on Assets	-0.45
Return on Capital Employed	-0.67

COM:VALERIOTX

Valerio Therapeutics

Last Close

0.08

25/11 08:24

Market Cap

15.49M

Beta: -

Volume Today

7.30K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.53
EV Multiple	-0.14

Metric
Days Sales Outstanding
Days Payables Outstanding	2.45K
Days Inventory Outstanding	251.76
Operating Cycle	1.25K
Cash Conversion Cycle	689.81
Asset Turnover	0.08

Metric
Operating Cash Flow	-19.64M
Free Cash Flow	-19.84M
Cash Flow to Debt	-1.28
Operating Cash Flow/Sales	-8.63
Free Cash Flow Yield	-0.50

Metric
Cash & Equivalents	7.20M
Accounts Receivable
Inventory	1.06
Goodwill	19.07M
Debt to Capitalization	0.76
Debt to Assets	0.23
Current Ratio	2.88
Quick Ratio	1.61

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.50
R&D to Revenue	5.46
SG&A to Revenue	1.83